



Date: May 19, 2025

#### MTPL/SECT/17/2025-26

То

The Secretary,
Listing Department,
The Manager,
Listing Department,

BSE Limited, National Stock Exchange of India Limited,

Phiroze Jeejeebhoy Towers, Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,

Dalal Street, G Block, Bandra Kurla Complex, Fort, Mumbai-400001. Bandra (E), Mumbai-400051.

Scrip Code: 533080 Symbol: MOLDTKPAC

Dear Sir/Madam,

#### Sub: Investor Presentation for the quarter and financial year ended on March 31, 2025.

Pursuant to the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements Regulations, 2015, we enclose herewith Investors Presentation for the quarter and financial year ended on March 31, 2025.

The same is also being uploaded on the website of the Company.

This is for your kind information and records.

Thanking you,

Yours faithfully, For Mold-Tek Packaging Limited

LAKSHMANA
RAO
JANUMAHANTI
JANUMAHANTI

BANUMAHANTI

BANUM

J. Lakshmana Rao Chairman & Managing Director DIN: 00649702

Encl: as above





## Q4 & FY 24-25

#### **Presentation**

(BSE: 533080; NSE:MOLDTKPAC)

May 19, 2025

# **Moldtek Snapshot**





39 YEARS OF EXPERIENCE



10 ISO CERTIFIED UNITS



PUBLICLY LISTED WITH INR ~1400 Cr Market cap



Established in 1986, one of the leading players in rigid plastic packaging in India. Publicly listed in 1993



10 Manufacturing Units, 2 stock points PAN India. Current installed Injection molding capacity of over 55,000 TPA



Pioneers in the field of In-Mold labelling (IML) in India. HD photographic labels, produced by 100% hands-free operation & are 100% recyclable.



MTPL commands strong presence across all major customers like Asian Paints, Castrol, Shell, Mondelez, Hindustan Unilever, etc.



Superior margins in the packaging industry due to the cost advantage emanating from backward integration



Asia's Best Company under a Billion 2023

dun & bradstreet

Best Packaging Company Award Thrice in a Row



3 INDIA STAR Awards



Best SME and Tech Savvy Award



# Pharma – Exceptional growth crossing break-even

By end of 1st year itself, company achieved over 50% capacity utilization to reach Breakeven level. Further capacity expansion across product mix planned by Q1/Q2.

# ٩ **Q4 Update** ŵ

# Aditya Birla steady growth & APIL IML adoption

As capacity utilization increases in the new plants, we foresee better margins and cost recovery. APIL and ABG also focusing on increased RCPP usage, for better sustainability

#### Printing capacity enhancement for handling seasonal demand

Added 2 new flexographic machines and balancing equipment to increase printing capacity by 50% to cater to expected rise in Q1 demand for IML products across verticals

## Ice cream season and Dairy take-off Food & FMCG sales

Food & FMCG sales of our thin walled products grow by an impressive 25% taking the annual growth to double digits for this segment. Detergents added as a strong new vertical



FY 25 paints growth of 6.79% fueled by increased demand from ABG and IML adoption by APIL


#### Q4 Update

- Capacity doubled at Cheyyar & Panipat plants for ABG. Satara plant capacity also increased by over 50%
- In-house adoption of HTL labels from APIL and ABG started
- Gearing up for higher usage of recycled PP to improve sustainability





Available Sizes
1 L, 4 L, 10 L, 20 L



#### **Q4** Update

- Improved IML and HTL adoption led to better margins
- Long term contracts to safe-guard volume share from industry leaders like Gulf, Shell, Castrol



Available Sizes

5 L, 6 L, 7.5 L, 10 L, 20 L, 25 L

#### Food & FMCG Packs - Thin-wall

FY 25 F&F growth of 11.76% as the new printing capacities started improving quarterly numbers

#### Q4 Update

- Launched new beverage packs for new local cafes and restaurants
- New nutritional powder packs take off for a major MNC brand
- RTE established as a strong segment with new clients like Marico, MOM etc.













"Meal of the Moment" – Our Packs are the New Normal for Ready-to-Eat
Industry which is growing at 28.2% in India



#### **Patented Square Packs**


FY 25 growth of 17.34% fueled by detergent segment and cashews



#### Q4 Update

- Capacity created at Daman & Panipat plants
- 10 Itr Q pack moulds established locally in 3 plants across India to reduce freight
- Started marketing our new additions to the Square Packs Segment – 2 &3 Ltr Square Packs for retail and confectionary segment







**Available Sizes** 

2 ltr, 3 ltr, 4 ltr, 5 ltr, 10 ltr 15 ltr & 17 ltr

#### Moldtek's D3 Suite

### **Powering Agile Pharma Development**

ISO 8 certified plant with Class 100k Cleanroom Facility and HEPA filtered AHUs with US and Canada DMF certification for all the products





#### PHARMA PORTFOLIO

#### **CROSSED BEP by Q4 FY25**





#### **Effervescent tubes**

- Capacity for highest selling SKU is planned to be doubled by Q2. This SKU has reached almost full utilization and is estimated to go further up.
- Improved version of spiral cap launched to be stable at high temperature and Rh levels, based on need from India's largest EV tablet manufacturer

#### **Tablet Containers with CT CR closures**

- Added numerous higher weight bottles using our in-house tool room to add to our product basket. Quick development of these packs gave great confidence in Moldtek
- Squeeze and lock cap is a revolutionary new idea designed to give child resistant functionality with a single piece construction. Our new design gives stability even at higher vacuum pressurized conditions
- 2 new products for a MNC company keep occupancy over 40-50% for IBM machines. Started coloured and White CRC supplies to over 3 customers



#### **Desiccant Canisters**

- Orders started for most high-selling size through a direct export order but domestic establishment is taking more time than anticipated. As product goes inside tablet container, the testing is more stringent
- New filling machine added to increase filling capacity. Dust-free version and online weight control added


Pharma adds to company's profits by end of 1st year

FY 25 pharma vertical grew every quarter ending up at 6.67 Cr. In Q4 of FY25

#### Q4 Update

- Moldtek's reputation in IML, combined with DMF facility with greatest hygiene standards has helped us to dominate the EV tubes and stoppers market for Nutraceuticals
- Voluminous orders from South and West based customers for 40, 60, 100cc SKUs among many others; while consistent orders in 150, 300 and 450cc SKUs of new shapes. New weights and shapes introduced
- White and coloured CRC orders from a west based MNC and a south based global player.





## **Future Roadmap in Pharma**

New land being acquired in Sultanpur for growth of pharma in product-wise capacity as well as entry into new product verticals

Establish ment

Product expansion

**Innovation** 

# IBM with clean room manufacturing

Several client audits cleared for regulatory DMF market. Received great feedback on our facilities and processes. Strong technical production and quality team drive continual improvement

# Expansion in all 3 product verticals of pharma

- Adding 2 new machines for a new tamper evident cap for a domestic client by end of Q1 FY26.
- We added over 12 new bottle SKUs, 2 sizes in child-resistant packaging, and 2 sizes in EV tubes based on concrete orders

# Several New product launches

28 mm CRC with tamper evidence – This product has huge demand but most companies still import from Europe and other countries at a huge price differential. We are also adding a feature to use this for injectables.





## **Key Financial Highlights – FY2025**

#### **Snapshot**

Finacial Performance & Highlights

#### Sales Volume


The Sales Volume recorded 38264MT in FY25 against 35661MT in FY24 - a growth of 7.30%.

#### Revenue

The Company recorded a total revenue of INR 781.32 cr. in FY25, compared to INR 698.65 cr. in last year – a growth of 12%

#### **Margins**

The EBIDTA for the FY25 is INR 143.86cr. against FY24 is INR 134.47 cr. a growth of 6.98%. PAT reduced marginally due to higher depreciation and finance costs.



## **Key Financial Highlights - Quarter**

#### **Snapshot**

Finacial Performance & Highlights

#### Sales Volume


The Sales Volume recorded 9734MT in Q4FY25 against 9071MT in Q4 FY24 - a growth of 7.31%.

#### Revenue

The Company recorded a total revenue of INR 202.61 cr. in Q4, compared to INR 176.87 cr. in last year Q4 – a growth of 14.55%.

#### **Margins**


The EBIDTA for the Q4FY25 is INR 39.08cr. against Q4FY24 is INR 35.78 cr. -a growth of 9.20%





## **Profit & Loss Statement**


	-							
PARTICULARS IN (RS. CRORE)	Q4 FY25	Q4 FY24	Q4oQ4 %	Q3 FY25	Q4oQ3 %	FY25	FY24	YoY %
Revenue	202.61	176.87	15%	190.69	6%	781.32	698.65	12%
Other Income	0.79	0.31	150%	0.16	396%	2.46	1.30	89%
Total Expenditure	164.32	141.40	16%	156.86	5%	639.92	565.47	13%
Material Cost	112.16	102.06	10%	111.51	1%	447.54	398.80	12%
Changes in FG & WIP	2.20	-4.41		-6.90		-7.28	-2.11	
Employee Benefit Expense	15.48	13.92	11%	15.72	-2%	60.91	50.28	21%
Other Expense	34.48	29.83	16%	36.53	-6%	138.76	118.50	17%
EBITDA	39.08	35.79	9%	33.98	15%	143.86	134.47	7%
EBITDA Margin(%)	19.29%	20.23%	-94 bps	17.82%	147 bps	18.41%	19.25%	-84 bps
EBITDA per KG	40.15	39.45	2%	36.72	9%	37.60	37.71	0%
Finance Costs	4.04	2.15	88%	3.43	18%	13.90	7.35	89%
Depreciation and Amortisation	12.81	10.03	28%	12.38	3%	48.68	38.50	26%
РВТ	22.23	23.60	-6%	18.18	22%	81.27	88.63	-8%
Tax Expense	5.96	5.63	6%	4.53	31%	20.72	22.04	-6%
PAT	16.27	17.97	-9%	13.64	19%	60.55	66.59	-9%
PAT Margin(%)	8.03%	10.16%	-213 bps	7.15%	88 bps	7.75%	9.53%	-178 bps
EPS Basic (Rs.)	4.90	5.41	-9%	4.11	19%	18.22	20.07	-9%

## **Customer Segment Analysis**









# THANK YOU